PD‐(L)1 inhibitors vs . chemotherapy vs . their combination in front‐line treatment for NSCLC: An indirect comparison-Reference-Cited by-全球学者库

PD‐(L)1 inhibitors vs . chemotherapy vs . their combination in front‐line treatment for NSCLC: An indirect comparison

Published:2019-05-10 Issue:11 Volume:145 Page:3011-3021
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Liang Hengrui¹,Liu Zhichao¹²,Cai Xiuyu³,Pan Zhenkui⁴,Chen Difei⁵,Li Caichen¹,Chen Yingying¹,He Jianxing¹²^ORCID,Liang Wenhua¹

Affiliation:

1. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory DiseaseGuangzhou Institute of Respiratory Health Guangzhou China

2. Department of Thoracic SurgeryShanghai Chest Hospital, Shanghai Jiao Tong University Shanghai China

3. Department of General Internal MedicineSun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou China

4. Department of OncologyQingdao Municipal Hospital, Qingdao Shandong China

5. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory DiseaseGuangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

Funder

National Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32366

Reference36 articles.

1. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer